New diabetes drug HRS-7535 shows promise in early trial
NCT ID NCT06393348
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested a new drug called HRS-7535 in 155 adults with type 2 diabetes whose blood sugar was not well controlled despite taking metformin and an SGLT2i. Participants received either HRS-7535 or a placebo for 16 weeks. The main goal was to see if the drug could lower HbA1c (a measure of average blood sugar) more than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-7535
What this could lead to
If it works, this could offer a new oral medication option to help people with type 2 diabetes better control their blood sugar and possibly lose weight.
What could go wrong
This is an early Phase 2 trial with only 155 people, so results may not apply to everyone. The drug may not prove effective or could have side effects not yet seen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangdong, Guangzhou, 51020, China